1307803-55-9

Usage

Uses

Used in Forensic Toxicology:
JWH 018 N-(5-hydroxypentyl) β-D-Glucuronide is used as a biomarker for the detection of synthetic cannabinoid exposure in forensic toxicology. Its presence in urine samples can indicate the consumption of JWH 018, which is essential for identifying cases of drug abuse and potential health risks associated with synthetic cannabinoid use.
Used in Research and Development:
In the field of research and development, JWH 018 N-(5-hydroxypentyl) β-D-Glucuronide is used as a reference compound for studying the metabolism and pharmacokinetics of synthetic cannabinoids. This helps researchers understand the behavior of these compounds in the human body and develop better detection methods and potential treatments for synthetic cannabinoid-related health issues.
Used in Drug Testing Laboratories:
JWH 018 N-(5-hydroxypentyl) β-D-Glucuronide is used as a target analyte in drug testing laboratories for the identification and quantification of synthetic cannabinoid metabolites in biological samples. This aids in the accurate assessment of synthetic cannabinoid use and contributes to the development of effective drug testing protocols and screening methods.

Upstream product

• 335161-21-2 (1-(5-hydroxypentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone 
• 2616-64-0 UDP-glucuronic acid 

Relevant academic research and scientific papers

Conjugation of synthetic cannabinoids JWH-018 and JWH-073, metabolites by human UDP-glucuronosyltransferases

K2, a synthetic cannabinoid (SC), is an emerging drug of abuse touted as "legal marijuana" and marketed to young teens and first-time drug users. Symptoms associated with K2 use include extreme agitation, syncope, tachycardia, and visual and auditory hallucinations. One major challenge to clinicians is the lack of clinical, pharmacological, and metabolic information for the detection and characterization of K2 and its metabolites in human samples. Information on the metabolic pathway of SCs is very limited. However, previous reports have shown the metabolites of these compounds are excreted primarily as glucuronic acid conjugates. Based on this information, this study evaluates nine human recombinant uridine diphosphate-glucuronosyltransferase (UGT) isoforms and human liver and intestinal microsomes for their ability to glucuronidate hydroxylated metabolites of 1-naphthalenyl-1(1- pentyl-1H-indol-3-yl)-methanone (JWH-018) and (1-butyl-1H-indol- 3-yl)-1-naphthalenyl-methanone (JWH-073), the two most common SCs found in K2 products. Conjugates were identified and characterized using liquid chromatography/tandem mass spectrometry, whereas kinetic parameters were quantified using high-performance liquid chromatography-UV-visible methods. UGT1A1, UGT1A3, UGT1A9, UGT1A10, and UGT2B7 were shown to be the major enzymes involved, showing relatively high affinity with Kmranging from 12 to 18 μM for some hydroxylated K2s. These UGTs also exhibited a high metabolic capacity for these compounds, which indicates that K2 metabolites may be rapidly glucuronidated and eliminated from the body. Studies of K2 metabolites will help future development and validation of a specific assay for K2 and its metabolites and will allow researchers to fully explore their pharmacological actions. Copyright